Shane Thomas Gleason Sells 3,858 Shares of InspireMD (NYSE:NSPR) Stock

InspireMD, Inc. (NYSE:NSPR) insider Shane Thomas Gleason sold 3,858 shares of the firm’s stock in a transaction dated Monday, January 27th. The stock was sold at an average price of $2.71, for a total transaction of $10,455.18. Following the transaction, the insider directly owned 1,135,319 shares in the company, valued at approximately $3,076,714.49. This represents a 0.34% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Shane Thomas Gleason also recently made the following trade(s):

• On Tuesday, May 19th, Shane Thomas Gleason sold 22,778 shares of InspireMD stock. The stock was sold at an average price of $1.01, for a total transaction of $23,005.78.

InspireMD Stock Performance

NYSE:NSPR opened at $1.00 on Friday. InspireMD, Inc. has a 52 week low of $0.97 and a 52 week high of $2.93. The firm has a market cap of $46.84 million, a price-to-earnings ratio of -1.33 and a beta of 0.82. The firm’s 50-day simple moving average is $1.38 and its 200 day simple moving average is $1.66.

InspireMD News Roundup

Here are the key news stories impacting InspireMD this week:

• Positive Sentiment: Wall Street still has a constructive view on InspireMD, with multiple analysts maintaining Buy ratings and a consensus price target well above the current share price. InspireMD (NSPR) Stock Forecast & Price Target
• Neutral Sentiment: The latest insider sale by Shane Thomas Gleason involved 3,858 shares and was disclosed as being related to tax withholding obligations from vested equity awards, which often makes the transaction less meaningful as a trading signal. SEC filing
• Neutral Sentiment: There were several earlier insider sales by the same executive this month and in prior months, but the reported amounts were relatively small and also tied to equity-award tax obligations. SEC filing
• Negative Sentiment: Multiple insider sales can still pressure sentiment because investors may interpret them as limited near-term confidence, especially with NSPR trading near its 52-week low and below key moving averages. SEC filing

Institutional Investors Weigh In On InspireMD

Hedge funds have recently made changes to their positions in the stock. Ghisallo Capital Management LLC acquired a new stake in InspireMD during the 3rd quarter worth approximately $2,221,000. Aberdeen Group plc acquired a new stake in InspireMD during the 3rd quarter worth approximately $5,979,000. Rosalind Advisors Inc. boosted its position in InspireMD by 70.6% during the 3rd quarter. Rosalind Advisors Inc. now owns 3,905,743 shares of the company’s stock worth $9,413,000 after buying an additional 1,616,644 shares during the period. Creative Planning acquired a new stake in InspireMD during the 2nd quarter worth approximately $44,000. Finally, Virtu Financial LLC acquired a new stake in InspireMD during the 4th quarter worth approximately $31,000. 44.78% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

NSPR has been the topic of several recent analyst reports. Piper Sandler reissued an “overweight” rating and issued a $3.00 target price (down from $4.00) on shares of InspireMD in a report on Tuesday, May 5th. Lake Street Capital set a $4.00 target price on shares of InspireMD in a report on Monday, May 4th. Loop Capital set a $5.00 target price on shares of InspireMD in a report on Tuesday, February 24th. Finally, Maxim Group initiated coverage on shares of InspireMD in a report on Monday, February 2nd. They issued a “buy” rating and a $6.00 target price on the stock. Three investment analysts have rated the stock with a Buy rating, According to MarketBeat, InspireMD has an average rating of “Buy” and a consensus price target of $4.50.

About InspireMD

InspireMD, Inc is a medical device company focused on developing next-generation stent technologies for cardiovascular and neurovascular interventions. The company’s core innovation lies in its MicroNet® mesh platform, a proprietary nanostructured covering designed to prevent embolic events during stent implantation. By integrating this fine mesh into traditional stent architectures, InspireMD aims to enhance safety and efficacy in the treatment of carotid artery disease and other vascular pathologies.

The company’s flagship offering, the CGuard® Embolic Prevention System (EPS), has received CE Mark approval and is commercially available in multiple international markets.